FDA Clears Organogenesis' Next Generation PuraPly Surgical Solution
Publish date: 2024-07-21
Benzinga
Aug. 15, 2022, 01:06 PM
- Organogenesis Holdings Inc (NASDAQ:ORGO) has received the FDA 510k Clearance for PuraPly MZ, a brand extension to the PuraPly product portfolio.
- Of the U.S.'s 40 to 50 million surgeries each year, up to 28% of surgical sites must be left open to heal.
- Related: Organogenesis' Q2 Operating Income Fell 50%, Lowers Annual Guidance.
- Organogenesis developed PuraPly MZ, a powder designed to support wound healing in deep, tunneling, and complex wounds to support clinicians and patients with these complex post-surgical wounds.
- PuraPly MZ consists of native structured collagen designed to allow for maximum coverage and maintenance of optimal contact with the contours of the wound surface to support healing.
- Price Action: ORGO shares are up 2.44% at $4.83 during the market session on the last check Monday.
SHARE THIS POST
Organogenesis NewsMORE
";}}tableString += "";}tableString += "";}}tableString += "";$('#detail-news-table').html(tableString);try { trackPI(); } catch (e) { }};function insertNewsHelp() {var help = "To give you an overview of the large number of messages that appear every day for a company, we have broken the news feed in the following categories:\u003cbr/\u003eRelevant : News from selected sources that deal specifically with this company \u003cbr/\u003eAll: All news about this company. \u003cbr/\u003eCompany News: News issued by the company directly.";$('#detail-news-table').html(help);try { trackPI(); } catch (e) { }};ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xopZ6vo2TAtbvCpKponpSWeqS4xJqprGWfp7Sius6gnKedo57AbrrEsatmn5WjsrOt06Kmp2Wgqr%2BivMuyZKytopy2pK3LZqqopKWptrC6jGpnbGlmbYF4fpU%3D